The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.

Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine FDA oversight as legal battle escalates.

The U.S. Food and Drug Administration (FDA) plans to take steps to limit the use of GLP-1 in non-FDA-approved compounded ...

The FDA has outlined numerous concerns about the sale and use of unapproved GLP-1 drugs for weight loss.  “FDA is aware that ...

Indiana lawmakers are weighing new guardrails around drug compounding amid warnings that patients are receiving powerful prescription treatments in settings that operate largely outside state ...

By Leah Douglas and Siddhi Mahatole Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it would take ...

The FDA announced Friday that it intends to restrict the active pharmaceutical ingredients of glucagon-like peptide-1 (GLP-1) receptor agonists used in unapproved compounded drugs that are being ...

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is ...

Whether it’s due to an ingredient allergy or other reasons, compounding pharmacies can help tailor a custom-made medication to meet your needs. And when drug shortages happen, they can play an ...